NovaBridge Biosciences
NASDAQ Global MarketTotal Valuation
NovaBridge Biosciences carries a market capitalization of 210.94M, placing it among publicly traded companies globally. Its enterprise value stands at 2.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 210.94M |
| Enterprise Value | 2.07B |
Share Statistics
NovaBridge Biosciences currently has 265.38M shares outstanding.
| Shares Outstanding | 265.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.71 |
| P/TBV Ratio | 9.84 |
| P/FCF Ratio | -178.19 |
| P/OCF Ratio | -178.19 |
Financial Position
NovaBridge Biosciences maintains a current ratio of 8.09, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 8.09 |
| Quick Ratio | 7.91 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -19.56 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NovaBridge Biosciences's stock has declined approximately -12.01923% over the past 52 weeks. The 50-day moving average sits at 1.78, while the 200-day moving average is 3.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | -12.01923% |
| 50-Day Moving Average | 1.78 |
| 200-Day Moving Average | 3.18 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -93.84M, while operating income came in at -94.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -94.27M |
| Pretax Income | -88.34M |
| Net Income | -46.27M |
| EBITDA | -93.84M |
| EBIT | -94.27M |
| Earnings Per Share (EPS) | -1.08 |
Balance Sheet
NovaBridge Biosciences holds 210.84M in cash and equivalents against 3.07M in total debt, resulting in a net debt position of -210.63M. Total book value stands at -1.33B, with working capital of 190.63M providing operational flexibility.
| Cash & Cash Equivalents | 210.84M |
| Total Debt | 3.07M |
| Net Debt | -210.63M |
| Equity (Book Value) | -1.33B |
| Book Value Per Share | -16.32 |
| Working Capital | 190.63M |
Cash Flow
NovaBridge Biosciences produced -12.76M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.76M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.76M |
| FCF Per Share | -0.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -2.54 |
| FCF Yield | -0.56 |
Scores
NovaBridge Biosciences posts an Altman Z-Score of 38.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 38.63 |